Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results